Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial
Highlights
- Nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, previously met its primary endpoint of reducing FVC decline at 52 weeks in the FIBRONEER-IPF trial.
- Extended follow-up data (averaging ~14.8 months) shows no significant difference in the composite endpoint of acute exacerbation, respiratory hospitalization, or death.
- The 18 mg BID dose was associated with a numerically lower risk of death (HR 0.66), though this did not reach statistical significance.
- The safety profile remains favorable, with low discontinuation rates due to adverse events compared to traditional antifibrotic therapies.
Background: The Challenge of Idiopathic Pulmonary Fibrosis
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.